CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Amgen INC (AMGN) / maridebart cafraglutide
Forward catalyst · AMGN

maridebart cafraglutide

Sponsor Amgen INC · listed as AMGN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

maridebart cafraglutide is a clinical-stage drug asset sponsored by Amgen INC, listed as AMGN. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Jan 21, 2027 (day precision, medium confidence), tied to trial NCT06858839. The asset is in Phase 3 and currently active not recruiting, studied in Obesity. It appears across 10 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-01-21
As disclosedJan 21, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06858839
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAmgen
Listed asAMGN
Condition(s)Obesity

All tracked catalysts for maridebart cafraglutide

DateEventConfidenceTrial
2027-01-21READOUTmediumNCT06858839
2027-04-27READOUTmediumNCT06987695
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More AMGN catalysts